乳癌治療薬の世界市場2019-2023

◆英語タイトル:Global Breast Cancer Therapeutics Market 2019-2023
◆商品コード:IRTNTR30504
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月13日
◆ページ数:137
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、乳癌治療薬の世界市場について調査・分析し、市場概要、市場環境、乳癌治療薬市場規模、製品別(標的療法、ホルモン療法、化学療法)分析、種類別(非浸潤性乳管癌、浸潤性乳管癌、トリプルネガティブ乳癌、炎症性乳癌、転移性乳癌)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・乳癌治療薬の世界市場概要
・乳癌治療薬の世界市場環境
・乳癌治療薬の世界市場動向
・乳癌治療薬の世界市場規模
・乳癌治療薬の世界市場:業界構造分析
・乳癌治療薬の世界市場:製品別(標的療法、ホルモン療法、化学療法)
・乳癌治療薬の世界市場:種類別(非浸潤性乳管癌、浸潤性乳管癌、トリプルネガティブ乳癌、炎症性乳癌、転移性乳癌)
・乳癌治療薬の世界市場:地域別市場規模・分析
・乳癌治療薬の北米市場規模・予測
・乳癌治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・乳癌治療薬のアジア太平洋市場規模・予測
・乳癌治療薬の主要国分析
・乳癌治療薬の世界市場:意思決定フレームワーク
・乳癌治療薬の世界市場:成長要因、課題
・乳癌治療薬の世界市場:競争環境
・乳癌治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、AstraZeneca、Eli Lilly、F. Hoffmann-La Roche、Novartis、Pfizerなどです。
【レポートの概要】

About this market
Emerging novel therapies to gain traction in the market. Therapies including combination therapies, vaccines, PARP inhibitors, and CDK inhibitors are emerging as innovative approaches to treat breasts cancer. Technavio’s analysts have predicted that the breast cancer therapeutics market will register a CAGR of close to 8% by 2023.
Market Overview
Rising number of patient supportive initiatives
To address the economic and emotional burden associated with cancer, manufacturers, governments, non-profit organizations, and healthcare providers are aiming at improving patient access to resources and bridge the substantial gaps in care.
Tendency of patients to prefer substitutes
Individuals with breast cancer often opt for mastectomy, lumpectomy, and radiation therapy to eliminate the tumor mass. However, efficient therapies including chemotherapy, and targeted and hormonal therapies are used to treat breast cancer. These surgeries act as substitutes and patients prefer these substitutes, which are expensive and can have a series of side effects.
For the detailed list of factors that will drive and challenge the growth of the breast cancer therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the emerging novel therapies and the rising number of patient supportive initiatives, will provide considerable growth opportunities to breast cancer therapeutics manufactures. AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, Novartis, and Pfizer are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Targeted therapy – Market size and forecast 2018-2023
• Hormonal therapy – Market size and forecast 2018-2023
• Chemotherapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Ductal carcinoma in situ
• Invasive Ductal Carcinoma
• Triple-negative breast cancer
• Inflammatory breast cancer
• Metastatic breast cancer
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Eli Lilly
• F. Hoffmann-La Roche
• Novartis
• Pfizer
PART 15: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global oncology drugs market
Exhibit 03: Segments of global oncology drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Molecules in the pipeline for different type of breast cancer
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Product – Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Targeted therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Targeted therapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Sales in $ millions from 2015-2017
Exhibit 24: Hormonal therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Hormonal therapy – Year-over-year growth 2019-2023 (%)
Exhibit 26: Chemotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Chemotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: First-in-class drugs for the treatment of breast cancer approved in 2017 and 2018
Exhibit 34: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: New drug approvals for breast cancer
Exhibit 43: Patient support programs
Exhibit 44: Biosimilars for Herceptin and Avastin
Exhibit 45: Impact of drivers and challenges
Exhibit 46: List of collaborations between manufacturers for the breast cancer therapies
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca – Vendor overview
Exhibit 53: AstraZeneca – Business segments
Exhibit 54: AstraZeneca – Organizational developments
Exhibit 55: AstraZeneca – Geographic focus
Exhibit 56: AstraZeneca – Key offerings
Exhibit 57: Eli Lilly – Vendor overview
Exhibit 58: Eli Lilly – Business segments
Exhibit 59: Eli Lilly – Organizational developments
Exhibit 60: Eli Lilly – Geographic focus
Exhibit 61: Eli Lilly – Segment focus
Exhibit 62: Eli Lilly – Key offerings
Exhibit 63: F. Hoffmann-La Roche – Vendor overview
Exhibit 64: F. Hoffmann-La Roche – Business segments
Exhibit 65: F. Hoffmann-La Roche – Organizational developments
Exhibit 66: F. Hoffmann-La Roche – Geographic focus
Exhibit 67: F. Hoffmann-La Roche – Segment focus
Exhibit 68: F. Hoffmann-La Roche – Key offerings
Exhibit 69: Novartis – Vendor overview
Exhibit 70: Novartis – Business segments
Exhibit 71: Novartis – Organizational developments
Exhibit 72: Novartis – Geographic focus
Exhibit 73: Novartis – Segment focus
Exhibit 74: Novartis – Key offerings
Exhibit 75: Pfizer – Vendor overview
Exhibit 76: Pfizer – Business segments
Exhibit 77: Pfizer – Organizational developments
Exhibit 78: Pfizer – Geographic focus
Exhibit 79: Pfizer – Segment focus
Exhibit 80: Pfizer – Key offerings
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: List of abbreviations



【掲載企業】

AstraZeneca、Eli Lilly、F. Hoffmann-La Roche、Novartis、Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[乳癌治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆